000169831 001__ 169831
000169831 005__ 20240229133656.0
000169831 0247_ $$2doi$$a10.1093/ije/dyab115
000169831 0247_ $$2pmid$$apmid:34259837
000169831 0247_ $$2ISSN$$a0300-5771
000169831 0247_ $$2ISSN$$a1464-3685
000169831 0247_ $$2altmetric$$aaltmetric:109501836
000169831 037__ $$aDKFZ-2021-01575
000169831 041__ $$aEnglish
000169831 082__ $$a610
000169831 1001_ $$00000-0003-1684-7428$$aPorta, Miquel$$b0
000169831 245__ $$aPlasma concentrations of persistent organic pollutants and pancreatic cancer risk.
000169831 260__ $$aOxford$$bOxford Univ. Press$$c2022
000169831 3367_ $$2DRIVER$$aarticle
000169831 3367_ $$2DataCite$$aOutput Types/Journal article
000169831 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1652441767_26048$$xReview Article
000169831 3367_ $$2BibTeX$$aARTICLE
000169831 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169831 3367_ $$00$$2EndNote$$aJournal Article
000169831 500__ $$a2022 May 9;51(2):479-490
000169831 520__ $$aFindings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts.We conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline.Some associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk.Individually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer.
000169831 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169831 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169831 650_7 $$2Other$$aPancreatic cancer
000169831 650_7 $$2Other$$abiomarkers
000169831 650_7 $$2Other$$aenvironmental health
000169831 650_7 $$2Other$$amethods
000169831 650_7 $$2Other$$apersistent organic pollutants
000169831 7001_ $$aGasull, Magda$$b1
000169831 7001_ $$aPumarega, José$$b2
000169831 7001_ $$aKiviranta, Hannu$$b3
000169831 7001_ $$aRantakokko, Panu$$b4
000169831 7001_ $$aRaaschou-Nielsen, Ole$$b5
000169831 7001_ $$aBergdahl, Ingvar A$$b6
000169831 7001_ $$aSandanger, Torkjel Manning$$b7
000169831 7001_ $$aAgudo, Antoni$$b8
000169831 7001_ $$aRylander, Charlotta$$b9
000169831 7001_ $$aNøst, Therese Haugdahl$$b10
000169831 7001_ $$aDonat-Vargas, Carolina$$b11
000169831 7001_ $$aAune, Dagfinn$$b12
000169831 7001_ $$aHeath, Alicia K$$b13
000169831 7001_ $$aCirera, Lluís$$b14
000169831 7001_ $$aGoñi-Irigoyen, Fernando$$b15
000169831 7001_ $$aAlguacil, Juan$$b16
000169831 7001_ $$aGiménez-Robert, Àlex$$b17
000169831 7001_ $$aTjønneland, Anne$$b18
000169831 7001_ $$aSund, Malin$$b19
000169831 7001_ $$aOvervad, Kim$$b20
000169831 7001_ $$aMancini, Francesca Romana$$b21
000169831 7001_ $$aRebours, Vinciane$$b22
000169831 7001_ $$aBoutron-Ruault, Marie-Christine$$b23
000169831 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b24$$udkfz
000169831 7001_ $$aSchulze, Matthias B$$b25
000169831 7001_ $$aTrichopoulou, Antonia$$b26
000169831 7001_ $$aPalli, Domenico$$b27
000169831 7001_ $$aGrioni, Sara$$b28
000169831 7001_ $$aTumino, Rosario$$b29
000169831 7001_ $$aNaccarati, Alessio$$b30
000169831 7001_ $$aPanico, Salvatore$$b31
000169831 7001_ $$aVermeulen, Roel$$b32
000169831 7001_ $$aQuirós, J Ramón$$b33
000169831 7001_ $$aRodríguez-Barranco, Miguel$$b34
000169831 7001_ $$aColorado-Yohar, Sandra M$$b35
000169831 7001_ $$aChirlaque, María-Dolores$$b36
000169831 7001_ $$aArdanaz, Eva$$b37
000169831 7001_ $$aWareham, Nick$$b38
000169831 7001_ $$aKey, Tim$$b39
000169831 7001_ $$aJohansson, Mattias$$b40
000169831 7001_ $$aMurphy, Neil$$b41
000169831 7001_ $$aFerrari, Pietro$$b42
000169831 7001_ $$aHuybrechts, Inge$$b43
000169831 7001_ $$aChajes, Veronique$$b44
000169831 7001_ $$aGonzalez, Carlos Alberto$$b45
000169831 7001_ $$ade-Mesquita, Bas Bueno-$$b46
000169831 7001_ $$aGunter, Marc$$b47
000169831 7001_ $$aWeiderpass, Elisabete$$b48
000169831 7001_ $$aRiboli, Elio$$b49
000169831 7001_ $$aDuell, Eric J$$b50
000169831 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b51$$udkfz
000169831 7001_ $$00000-0001-8935-4566$$aVineis, Paolo$$b52
000169831 773__ $$0PERI:(DE-600)1494592-7$$a10.1093/ije/dyab115$$gp. dyab115$$n2$$p479-490$$tInternational journal of epidemiology$$v51$$x1464-3685$$y2022
000169831 909CO $$ooai:inrepo02.dkfz.de:169831$$pVDB
000169831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000169831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b51$$kDKFZ
000169831 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169831 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169831 9141_ $$y2021
000169831 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000169831 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000169831 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000169831 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-08$$wger
000169831 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J EPIDEMIOL : 2021$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000169831 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J EPIDEMIOL : 2021$$d2022-11-08
000169831 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000169831 980__ $$ajournal
000169831 980__ $$aVDB
000169831 980__ $$aI:(DE-He78)C020-20160331
000169831 980__ $$aUNRESTRICTED